eeroem magdated

ATTORNEY'S DOCKET NUMBER

	T	RANSMITTA	AL LETTER T	PC9824AJTJ											
		PATEN	NT AND TRA												
		DESIGNAT	ED/ELECTE	U.S. APPLICATION NO. (ICknown, see 37 C.F.R. L.5) Not yet assign 69 / 380 88 5											
				G UNDER 35 U.S.C. 371	07/20002										
		ATIONAL APPL /00937	ICATION NO.	PRIORITY DATE CLAIMED July 1, 1997 (07.01.1997)											
TIT	TITLE OF INVENTION														
DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE															
APPLICANT(S) FOR DO/EO/US															
William John CURTALO and Hylar Lewis FRIEDMAN															
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:															
1.	\boxtimes	This is the FIRST submission of items concerning a filing under 35 U.S.C. 371.													
2.		This is the SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.													
3.	\boxtimes	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).													
4.	\boxtimes	A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date.													
5.	\boxtimes	A copy of the International Application as filed (35 U.S.C.: 371(c)(2))													
		a. is transmitted herewith (required only if not transmitted by the International Bureau).													
		b. 🛛	has been transm	itted by the International Bureau.											
c. is not required, as the application was filed in the United States Receiving Office (RO/US).															
6.		A translation of the International Application into English (35 U.S.C. 371(c)(2)).													
7.	\boxtimes	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))													
		a. are transmitted herewith (required only if not transmitted by the International Bureau).													
		b. 🔲	have been transi	nitted by the International Bureau.											
		c. 🔲	have not been m	ade; however, the time limit for making such	amendments has NOT expired.										
		d.	have not been m	ade and will not be made.	•										
8.		A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).													
9.	\boxtimes	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).													
10.		A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).													
Items 11. To 16. Below concern other documents(s) or information included:															
11.	\boxtimes	An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.													
12.		An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.													
13.	\boxtimes	A FIRST preliminary amendment.													
	☐ A SECOND or SUBSEQUENT preliminary amendment.														
14.		A substitute specification.													
15.		A change of power of attorney and/or address letter.													
16.		Other items or in	Other items or information:												

514 Rec'd PCT/PTO 0 7 SEP 1999

PCT Applicant's Guide - Volume II - National Cha

	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) Not yet assigned 09/38085 PCT/IB98/00937							ATTORNEY'S DOCKET NUMBER PC9824A				
	17. 🛛 The									PTO USE ONLY		
		NAL FEE (37 CFR 1.4										
	⊠ Search	Report has been prepared b										
	Internat	ional preliminary examinat										
		rnational preliminary exami rnational search fee paid to										
		Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO\$970.00										
		ional preliminary examinat ns satisfied provisions of PO										
		ENT	\$840.00									
		00 for furnishing the oath caimed priority date (37 CFF	\$									
	CLAIMS	NUMBER FILED	NUMBER	BER EXTRA			RATE					
	Total Claims	53 - 20 =	33		X \$		18.00	\$594.00				
	Independent Claims	6 - 3 =	3		X \$;	78.00	\$234.00				
إ	MULTIPLE DEI	ULTIPLE DEPENDENT CLAIM(s) (if applicable) + \$260.00							\$			
Õ			\$1,668.00	\$1,668.00								
j		Reduction by ½ for filing by small entity, if applicable. Verified Small Entity Statement nust also be filed. (Note: 37 CFR 1.9, 1.27, 1.28)								· _		
V M			\$1,668.00)								
=	Processing fee of \$130.00 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).											
٥				тот	TAL N	ΑT	IONAL FEE =	\$1,668.00)	·		
F. (L.)	_	ne enclosed assignment (37 appropriate cover sheet (3'		_			+	\$				
₫[TOT	AL FE	ES	ENCLOSED =	\$1,668.00)			
g				int to be: unded	\$ '							
			Ch	arged	\$							
	a.	check in the amount of	\$ to co	ver the abo	ve fees	is e	enclosed.					
	b. Please charge my Deposit Account No. 16-1445 in the amount of \$ 1,668.00 to cover the above fees. A duplicate copy of this sheet is enclosed.											
	c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No.16-1445. A duplicate copy of this sheet is enclosed.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.												
	SEND ALL CO	RRESPONDENCE TO		J. N.	544-							
	Gregg C. B	iregg C. Benson Sig							rajure)			
	Pfizer Inc Jam							es T. Jones				
•	Eastern Point Road, Groton, CT 06340											
		30,5 Reg							61 stration Number			
Kegi									station Number			